Ageing in China: The Implications for Healthcare
Published in eyeforpharma 12 December by Marc Yates
China’s population has aged much faster than other populations, and this rapid ageing poses challenges to healthcare, among which the most common are a surging healthcare expenditure and a rising difficulty in managing the 'iron triangle'. China’s population has aged much faster than other populations, and the proportion of elderly among the total population is set to remain very high for years to come. The average time taken by developed countries for the percentage of the population above 65 years old to increase from 7% to 17% was 60 years, but China is expected to take only 30 years to reach the same level. By 2050, the proportion of the population over 65 in China is projected to reach 34%, which is comparable with Denmark, and much higher than the US (26%). Increased longevity and lower fertility rate are typically the two main factors that contribute to an ageing population. In the case of China, the strict family planning policy (one-child policy) implemented in 1980 has played a key role in the country’s rapid shift in population structure. As each family is only allowed to have one child, China’s fertility rate has dropped sharply in the wake of the policy,…
Supporting the babies of Forever Angels this holiday
This year, we will be donating US$4500 to the charity Forever Angels
As in previous years, we are once again delighted to be making an annual contribution to our chosen charity, Forever Angels. This is based on a US$2,000 donation that we are making on behalf of our clients in lieu of Season's Greetings cards. In addition a further US$2,500 has been raised by our employees through various fund raising activities that have taken place across our global offices over the past year.
The patient journey: Time to look beyond the physician?
Treatment initiation is a key focus for many pharma companies as part of their strategy to increase script writing and drive greater revenues.
However a recent study demonstrated that physicians spend as little as 49 seconds in dealing with a new treatment initiation with their patients.
So it is no surprise that more and more pharma marketers are steadily looking beyond the physician in order to improve patient engagement.
In this webinar Director Katrina Johnson and Associate Director Kate Hanson explore the ways that patient journey research can aid development of an effective "beyond the pill" strategy, leading to greater patient engagement and improved treatment outcomes.
Statistics and bikinis – 2 men united
I want to write today about 2 men that between them have reminded me of a fine line that we have to tread every time we analyse a dataset...
The first is Professor Aaron Levenstein. In truth there’s not too much to say about him, he was associate professor emeritus at Baruch College. He taught there for a grand total of 20 years, so I imagine that there are a lot of alumni of the college who have fond memories of him, if you happen to be reading this piece then let me know I’d like to hear what he was like as a man. His most widely published book is the well respected title “Escape to Freedom: The Story of the International Rescue Committee”. It’s a chronicle of some very dark times in the world’s history and yet it focusses on a positive outcome that is the IRC and the work it has done since its inception during WWII. I’m not about to review the book, there are plenty of other people who have done that. What has struck me is how he is remembered for a simple catchphrase, probably meant as a throwaway line, although it does emphasise a lot of the challenges we face when writing reports and interpreting research data.
5 years on from the Brazilian Generics Drugs Act, is there still an opportunity for branded originator drugs?
Published in eyeforpharma 10 November by Paul Reed
In 2009 the Brazilian government passed the Generics Drugs Act; one of numerous initiatives intended to reduce spend on originator branded drugs, whilst boosting generic drug prescription and supporting the domestic drug industry.
5 years on from the act, how successful have the Brazilian government been in advancing the local pharmaceutical players while reducing branded originator drugs spend? And importantly, is there still an opportunity for branded originator drugs?